Eli Lilly Highlights Positive Foundayo Data At Obesity Conference - Eli Lilly (NYSE:LLY)

Eli Lilly Highlights Positive Foundayo Data At Obesity Conference - Eli Lilly (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) traded higher on Friday after new late-stage trial data highlighted significant weight reduction in older adults using Foundayo. The drugmaker presented updated analyses from its Phase 3 ATTAIN studies during the European Congress on Obesity in Istanbul. According to a press release, the oral GLP-1 treatment delivered double-digit weight loss in some patients aged 65 and older. Older Adults Show Strong Weight Red…